1. Introduction {#s1}
===============

Statins are inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which catalyses the rate-limiting step in cholesterol formation. Accumulating studies have shown that statins can not only reduce serum total and low-density lipoprotein (LDL) cholesterol concentrations, but also effectively decrease ischemic cardiovascular disease related morbidity and mortality.[@b1] A meta-analysis of data from nine randomized controlled trials (RCTs) including 19,569 elderly patients with coronary heart disease aged from 65 to 82 years confirmed that multiple clinical outcomes were better in statin-treated patients than in placebo controls.[@b2] Many studies have demonstrated that statins are well tolerated by most elderly patients while they are less likely to receive statin treatment compared with the younger ones.[@b3] In a retrospective study on Canadian residents aged \> 65 years with a history of cardiovascular disease or diabetes, the likelihood of statin prescription decreased by 6.4% with each year of increasing age.[@b4] Concerns about the increased risk of adverse events, especially cancer risk, might contribute to the under-prescription of statins in older patients.

For more than a decade, the scientific debate on the association of statin treatment with cancer risk has been unsettled. A considerable studies found that statin treatment has no relationship with cancer risk, or some even revealed that statin may prevent cancer.[@b5]--[@b8] However, some studies yielded different results. For example, experimental studies suggested that statins may be carcinogenic.[@b9] Clinical studies also showed a significant increased incidence of cancer in the patients with statin treatment, including older people.[@b10],[@b11] Whether statin use increases cancer risk is still in debate. Reports about the effect of the statin therapy on the incidence of cancer for the older adults are relatively few. The aim of this study was to systematically review and evaluate the evidence on the association between statin therapy and overall cancer risk in people aged \> 60 years.

2. Methods {#s2}
==========

2.1. Search strategy {#s2a}
--------------------

To obtain all of the original studies which compared statin therapy with placebo or usual care, including both primary and secondary prevention trials, we searched potentially eligible trials in the electronic databases PubMed and Cochrane Central Register of Controlled Trials upto September 2015. A combination of Medical Subject Headings (MeSH) terms or free text keywords was used without language restrictions: "hydroxymethylglutaryl coenzyme A reductase inhibitor(s)" or "HMG-CoA reductase inhibitor(s)" or "anticholesterolaemic agent(s)" or "statin(s)" or "pravastatin" or "fluvastatin" or "simvastatin" or "atorvastatin" or "rosuvastatin" or "lovastatin" AND "randomized controlled trials" AND "aged" or "elderly" or "over 60 years old" AND "neoplasm(s)" or "cancer(s)" or "Tumors" or "Neoplasia" or "malignancy(ies)". Reference lists of the retrieved articles were also reviewed. We did not contact authors of the primary studies for additional information.

2.2. Selection criteria {#s2b}
-----------------------

Studies were included in this meta-analysis if they met the following criteria: (1) double-blinded, randomized comparison of statin versus inactive control (placebo or no statins); (2) average age of study participants \> 60 years or presence of subgroup analyses limited to participants \> 60 years of age; (3) duration of the randomized portion of the study at least one year, with at least 50% of the randomized participants completing one year of treatment; and (4) report of cancer incidence.

2.3. Data extraction {#s2c}
--------------------

Two investigators (Liu HW and Bian SY) independently extracted the data. We reviewed article titles and abstracts from the initial search and excluded those that did not meet the inclusion criteria. Articles included in the study were completely reviewed. Any disagreement was resolved by discussion.

For each eligible study, the following details were extracted from the published manuscript: allocation, year of publication, duration of follow-up, sample size of each treatment, mean age of participants, type of statin and newly diagnosed cancer over the period of follow-up.

2.4. Statistical analysis {#s2d}
-------------------------

### 2.4.1. Risk of bias assessment of included studies {#s2d1}

The probability of potential publication bias existing among the included studies was estimated by Begg\'s funnel plots.[@b12] The methodological quality of included studies was assessed using the criteria outlined in the Cochrane Handbook for Systematic Reviews, using the following domains: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting bias (reporting bias) and other bias (sponsorship). Each domain was assessed, graded as high, low or unclear risk, then a risk of bias graph was generated. In the graph of bias risk assessment, "blank space" meant "not clear", "red" meant "no", and "green" meant "yes", respectively. The more "green" the graph showed, the low bias risk and higher quality the trials had.

### 2.4.2. Data synthesis {#s2d2}

We evaluated the statistical heterogeneity between trials with the *I*^2^ value \[with 95% confidence intervals (CIs)\], which is derived from RevMan 5.3 software (Cochrane). Random-effect meta-analysis was performed instead of the fixed-effect model because the former approach provides a more conservative assessment of the average effect size. Odds ratios (ORs) and 95% CIs were calculated using binary data. We conducted meta-analyses that included all trials, different types of statins (pravastatin, simvastatin, atorvastatin, fluvastatin, lovastatin and rosuvastatin), and different chemical properties of the statins \[hydrophilic (pravastatin and rosuvastatin), or lipophilic (simvastatin, atorvastatin, fluvastatin and lovastatin)\].

3. Results {#s3}
==========

3.1. Study characteristics and quality assessment {#s3a}
-------------------------------------------------

A flow chart of study selection for this meta-analysis is shown in [Figure 1](#jgc-13-08-693-g001){ref-type="fig"}. Briefly, of the 464 initial hits, 33 studies were retrieved for more detailed evaluation, and 12 RCTs fulfilling the eligibility criteria were finally included in the analyses. A total of 62,927 patients (31,517 assigned to statin therapy group and 31,410 to control group), with a follow-up duration of 1.9--5.4 years were identifed.[@b11],[@b13]--[@b23] Basic characteristics of the included trials are outlined in [Table 1](#jgc-13-08-693-t01){ref-type="table"}. The absence of asymmetry of the Begg\'s funnel plots indicates that there was no potential publication bias ([Figure 2](#jgc-13-08-693-g002){ref-type="fig"}).

![Flow diagram of screened, excluded and analyzed publications.](jgc-13-08-693-g001){#jgc-13-08-693-g001}

###### Characteristics of the twelve randomized controlled statins trials included in the meta-analysis.

  Study                                      Countries                      Year of publication      Agent       No. of subjects (statin/control)   Mean age, yrs   Mean follow-up, yrs                                         Primary endpoint                                          Incident cancer (statin/control), *n* (%)
  ---------------------- ------------------------------------------------- --------------------- -------------- ---------------------------------- --------------- --------------------- ----------------------------------------------------------------------------------------------- -------------------------------------------
  4S[@b13], [@b43]                       Nordic countries                       1997, 1996        Simvastatin             1021 (518/503)                 67                 5.4                                            All-cause and CHD mortality                                               24 (4.6%)/30 (6.0%)
  AFCAPS/TexCAPS[@b14]                          USA                                1998            Lovastatin             997 (499/498)                  63                 5.2                                         First acute major coronary events                                            32 (6.4%)/28 (5.6%)
  SCAT[@b15]                                  Canada                               2000           Simvastatin             460 (230/230)                  61                  4                                                    QCA measures                                                       23 (10%)/13 (0.4%)
  GISSI[@b16]                                  Italy                               2000           Pravastatin            4271 (2138/2133)                60                  2                            Death, non-fatal myocardial infarction, and non-fatal stroke                               15 (0.7%)/24 (1.1%)
  LIPID[@b17]                         Australia, New Zealand                       2001           Pravastatin            3514 (1741/1773)               68.8                 6                                                    CHD mortality                                                     367 (8.4%)/324 (8.9%)
  ALLHAT-LLT[@b18]         US, Puerto Rico,US Virgin, Islands and Canada           2002           Pravastatin           10355 (5170/5185)                66                 4.8                                                All-cause mortality                                                  378 (7.3%)/369 (7.1%)
  HPS[@b19]                               United Kingdom                           2002           Simvastatin          20536 (10269/10267)               64                  5                                                 All-cause mortality                                                  814 (7.9%)/803 (7.8%)
  LIPS[@b20]                          Europe, Canada, Brazil                       2002           Fluvastatin             1677 (844/833)                 60                 3.9                                                       MACE                                                           46 (5.5%)/49 (5.9%)
  PROSPER[@b11]                  Scotland, Ireland,The Netherlands                 2002           Pravastatin            5804 (2891/2913)                75                 3.2           A composite of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke             245 (8.5%)/199 (6.8%)
  ASCOT-LLA[@b21]                  Nordic countries, UK, Ireland                   2011           Atorvastatin          10305 (5168/5137)                63                 3.3                            A composite of nonfatal myocardial infarction and fatal CHD                               81 (1.6%)/87 (1.7%)
  CARDS[@b22]                         United Kingdom, Ireland                      2006           Atorvastatin           2838 (1428/1410)                62                 3.9                    Acute coronary heart disease events, coronary revascularizations, or stroke                       20 (1.4%)/30 (2.1%)
  JUPITER[@b23]           North America, South America, Europe and Africa          2010           Rosuvastatin           5695 (2878/2817)                74                 1.9                                               Cardiovascular event                                                  144 (2.3%)/155 (2.5%)

CHD: coronary heart disease; MACE: major adverse cardiovascular events, including cardiac death, nonfatal myocardial infarction and target vessel revascularization; QCA: quantitative coronary angiography.
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Quality assessments of these RCTs are shown in [Figure 3](#jgc-13-08-693-g003){ref-type="fig"}. Most of the bias risk graphs display green, meaning that all the trials are of high quality.

3.2. Effects of statin therapy on the incidence of cancer {#s3b}
---------------------------------------------------------

The statin therapy did not affect the overall incidence of cancer in people over 60 years old (OR = 1.03, 95% CI: 0.94--1.14, *P* = 0.52; [Figure 4](#jgc-13-08-693-g004){ref-type="fig"}). The subgroup analyses of the individual statin revealed no significant effect on the incidence of cancer in aged people ([Figure 5](#jgc-13-08-693-g005){ref-type="fig"}): pravastatin therapy (OR = 1.11, 95% CI: 0.96--1.30, *P* = 0.17), simvastatin therapy (OR = 1.05, 95% CI: 0.75--1.47, *P* = 0.77), atorvastatin therapy (OR = 0.85, 95% CI: 0.63--1.14, *P* = 0.27), fluvastatin therapy (OR = 0.92, 95% CI: 0.61--1.40, *P* = 0.70), lovastatin therapy (OR = 1.15, 95% CI: 0.68--1.94, *P* = 0.60) and rosuvastatin therapy (OR = 0.90, 95% CI: 0.72--1.14, *P* = 0.40). In another analysis grouped statins by different chemical properties showed that neither the hydrophilic (OR = 1.07, 95% CI: 0.92--1.24, *P* = 0.38) nor lipophilic statins (OR = 0.99, 95% CI: 0.87--1.11, *P* = 0.81) affected the incidence of cancer in the elderly patients ([Figure 6](#jgc-13-08-693-g006){ref-type="fig"}).
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4. Discussion {#s4}
=============

The present meta-analysis showed that statins therapy did not increase the overall incidence of cancer in people aged over 60 years. In China, 60+ years are usually denoted as old age, while most developed western countries set the age of 60 to 65 for retirement and old-age social programs eligibility. Then, in order to provide more evidence for Chinese doctors, we only included RCTs when their study participants\' average age \> 60 years or presents subgroup analyses limited to participants \> 60 years of age.

Although RCTs are considered as the "gold standard" and provide the highest evidence for internal validity, controlling for potential confounders and effect modifiers, they are also most unlikely to miss events owing to close follow-up. Moreover, they have the disadvantage of relatively small size, so might not be adequately powered to detect a true effect, especially when events are rare, such as cancer.[@b24] Meta-analyses are considered as a valuable tool for studying this kind of rare and unintended effects of treatment. The results of this 12 RCTs meta-analysis were relatively stable according to sensitivity analysis. Begg\'s funnel plot showed no underlying publication bias and the bias risk graph indicated that all the included trials are highly qualified, so that bias due to differential attrition was unlikely to be an issue.

Our ﬁndings were in line with the previous meta-analysis of statin use and overall cancer risk in the elderly patients.[@b2] The subgroup analyses of the individual statin also found no substantial evidence for increasing cancer risk among statin users as compared with non-users. Among the studies selected for our meta-analysis, only two RCTs have reported an increased risk of cancer in the statin group compared to the placebo group. The PROSPER study,[@b11] which is the only randomized placebo controlled study to evaluate pravastatin in a unique population of elderly patients, found a 1.25 increased risk for cancer incidence for the pravastatin-treated patients compared to the placebo group. However, when the PROSPER trial extended follow-up period to 14 years, no relationship was found between statin use and cancer risks.[@b25] The LIPID trial also indicated an increased cancer risk in the elderly patients assigned to pravastatin treatment compared to placebo group.[@b17] Consist with these results, a meta-analysis of 12 RCTs showed that pravastatin therapy presented an increasing risk of cancer incidence with advancing patient age.[@b26] Our meta-analysis only included four RCTs of pravastatin, the different inclusion criteria might explain in part the contrary results. Cancer is an endpoint that needs to be followed-up for at least 10 years. Given to the relatively shorter follow-up period, it is too early to say whether some statins might have a carcinogenic effect for some cancer types. Nevertheless, the findings on pravastatin require cautious interpretation and need to be confirmed by further studies.
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The other subgroup analysis of statins with different chemical properties showed that neither the hydrophilic nor lipophilic affected the incidence of cancer in people aged \> 60 years, which are also in accord with previous reports.[@b27],[@b28] With respect to statin type, it has been hypothesized that only lipophilic statins can potentially be capable of inhibiting tumor development; in contrast, hydrophilic statins could be expected to promote tumor development.[@b29] However, clinical studies yielded conflicting results. Several RCTs of lipophilic statin therapy have not reported an increased risk of cancer.[@b14],[@b19],[@b30] In a recently published study, lipophilic statin was reported to play a therapeutic role in cancer treatment.[@b31] Different from lipophilic statins, results from hydrophilic statins are inconsistent. Duncan, *et al*.,[@b32] suggested that pravastatin may promote the development of cancer by inducing mevalonate synthesis in extrahepatic tissues. The post hoc analysis in the JUPITER found that high-intensity rosuvastatin (another hydrophilic statin) therapy achieved LDL-C levels \< 30 mg/dL but not associated with increased cancer risk.[@b33] Whether hydrophilic or lipophilic properties of statin have relationship to incident cancer required further discussion.

The present meta-analysis also failed to find favor results for statins as antitumor agents. Lipid metabolism is involved in the regulation of key cellular processes such as proliferation, differentiation and apoptosis. Statins may inhibit HMG-CoA reductase to lower the concentration of mevalonate, thereby decreasing the amount of isoprenylated intermediates that are known to affect signaling pathways from cancer formation to progression.[@b34],[@b35] *In vitro*/*in vivo* evidences have shown promising results for the use of statins in the treatment of various human malignancies.[@b36]--[@b39] However, the epidemiological data and several meta-analyses failed to find conclusive results, for example, results of statin on colorectal cancer ranging from very protective,[@b40] to moderately harmful.[@b41] As we known, cancer is not a homogenous disease entity, and overall cancer risk is not a very sensitive outcome. Therefore, the effects of statins might significantly differ according to anatomical site and molecular type. More investigations are needed to assess the effects of statins for the treatment of particular cancer type.

Several limitations of our study should be noted. First, the number of studies included in our meta-analysis is limited, especially for some individual statin. Second, analysis from subgroups should be interpreted with caution. The results from several included studies were obtained from subgroup data and not all studies population. Power is also likely to be limited in a subgroup analysis and the risks of obtaining spurious results are higher due to the inability of subgroups to account for multiple hypotheses assumed in the overall trial.[@b42] Third, studies included in this study had a relatively shorter follow-up duration (1.9--5.4 years). Given that many individuals are treated with statins for decades, this duration of time may not be adequate to fully assess cancer risk.

In summary, meta-analyses of 12 large RCTs of statins showed that the statin therapy did not affect the overall incidence of cancer, subgroup analyses showed that neither the variety nor the chemical properties of statins affected the incidence of cancer in people aged \> 60 years. These findings are limited by the relatively short follow-up duration of the included studies. More uniform reporting of cancer outcomes and longer follow-up periods are needed to firmly establish the role of statins in cancer development, particularly in people aged over 60 years.

[^1]: \*The first two authors contributed equally to this paper.
